Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing
and trading of medicines[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 63.0
- High / Low ₹ 141 / 47.2
- Stock P/E 10.3
- Book Value ₹ 36.3
- Dividend Yield 0.79 %
- ROCE 27.1 %
- ROE 26.3 %
- Face Value ₹ 10.0
Pros
Cons
- Company has high debtors of 188 days.
- Working capital days have increased from 55.6 days to 112 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 114 | 131 | |
| 85 | 104 | 114 | |
| Operating Profit | 7 | 9 | 17 |
| OPM % | 8% | 8% | 13% |
| 1 | 1 | 1 | |
| Interest | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 7 | 13 |
| Tax % | 29% | 27% | 28% |
| 3 | 5 | 10 | |
| EPS in Rs | 5.59 | ||
| Dividend Payout % | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 115% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -55% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 17 |
| Reserves | 12 | 17 | 45 |
| 19 | 26 | 25 | |
| 38 | 54 | 48 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 4 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 120 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5 | -5 | -13 | |
| -5 | -0 | 26 | |
| 1 | 5 | -4 | |
| Net Cash Flow | 1 | -0 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 128 | 159 | 188 |
| Inventory Days | 96 | 192 | 249 |
| Days Payable | 274 | 413 | 412 |
| Cash Conversion Cycle | -50 | -62 | 25 |
| Working Capital Days | 16 | 39 | 112 |
| ROCE % | 24% | 27% |
Documents
Announcements
-
Copy of Newspaper Publication
5 September 2025 - 25th AGM on Sep 29, 2025 at 1:00 PM via VC; notice and e-voting published Sep 05, 2025.
-
Shareholders meeting
4 September 2025 - 25th AGM on Sept 29, 2025; appoint VDS & Co. auditors; reappoint director; ratify cost auditor Rs.35,000.
-
Record Date
4 September 2025 - Record date Sept 22, 2025; books closed Sept 23–29, 2025 for AGM.
-
Shareholders meeting
4 September 2025 - Appointed Agrawal & Maheshwari as secretarial auditor FY2025-26; AGM scheduled 29 Sep 2025, 1:00 PM via VC/OAVM.
-
Outcome of Board Meeting
4 September 2025 - Approved 25th AGM on 29 Sep 2025; appointed Agrawal & Maheshwari as secretarial auditor for FY2025-26.
Business Overview:[1][2]
ZDL is a manufacturer of a range of healthcare drugs and allied products
which includes pharmaceutical formulations. It also caters to a diverse range of customers and generates revenue through various avenues, such as marketing of branded generic drugs, third-party job work manufacturing, government and institutional business, and exports through merchant dealers.